3 results
Primary Core: to demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression, measured by EDSS. Main secondary objectives Core: to demonstrate the efficacy in delaying the time to 3-month…
Primary: To compare the pharmacokinetics (PK) of the once daily (QD) and once weekly (QW) formulations of setmelanotideSecondary Objectives:To assess the safety of the QW formulation of setmelanotide with up to 6 months (26 weeks) of drug…
Primary• To evaluate the safety and tolerability of AMG 199 in adult subjects• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) Secondary• To characterize the PK of AMG 199 • To evaluate preliminary anti-tumor…